OOIR: Observatory of International Research

Papers

(The H4-Index of Annals of Neurology is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis	362
Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)	161
Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial	157
Guillain‐Barré Syndrome following ChAdOx1‐S/nCoV‐19 Vaccine	157
ANA Investigates: Neurological Complications of COVID‐19 Vaccines	148
Role of B Cells in Multiple Sclerosis and Related Disorders	145
Gut Microbiome in Progressive Multiple Sclerosis	141
Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination	134
Aerobic Exercise Alters Brain Function and Structure in Parkinson's Disease: A Randomized Controlled Trial	132
COVID‐19 Vaccine Response in People with Multiple Sclerosis	120
Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi‐Omics	118
The Impact of SARS‐CoV‐2 on Stroke Epidemiology and Care: A Meta‐Analysis	105
COVID‐19 Vaccine‐Associated Cerebral Venous Thrombosis in Germany	105
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker	92
Postvaccinal Encephalitis after ChAdOx1 nCov‐19	88
Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis	86
Neurological Events Reported after COVID‐19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System	82
Preservation of Brain Activity in Unresponsive Patients Identifies MCS Star	81
Incidence, clinical, risk factors and outcomes of Guillain‐Barré in Covid‐19	81
Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease	81
SARS‐CoV‐2 and Mitochondrial Proteins in Neural‐Derived Exosomes of COVID‐19	79
Blood–Brain Barrier Breakdown in Relationship to Alzheimer and Vascular Disease	76
Magnetic ResonanceImages Implicate That Glymphatic Alterations Mediate Cognitive Dysfunction inAlzheimer Disease	74
Pediatric Ischemic Stroke: An Infrequent Complication of SARS‐CoV‐2	74
Probabilistic Mapping of Deep Brain Stimulation: Insights from 15 Years of Therapy	73

Multisystem Involvement in Post‐Acute Sequelae of Coronavirus Disease 19	72
DBS of Thalamic Centromedian Nucleus for Lennox–Gastaut Syndrome (ESTEL Trial)	70
Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019	68
Inflammatory Cytokine Patterns Associated with Neurological Diseases in Coronavirus Disease 2019	67
Amylin Analog Pramlintide Induces Migraine‐like Attacks in Patients	67
An Overview of Monkeypox Virus and Its Neuroinvasive Potential	67
Long‐Term Cognitive Outcome in Anti–N‐Methyl‐D‐Aspartate Receptor Encephalitis	65
Induction of Human Motor Cortex Plasticity by Theta Burst Transcranial Ultrasound Stimulation	65
Seizures after Ischemic Stroke: A Matched Multicenter Study	64
Alpha‐Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure	63
Increasing Brain Gamma Activity Improves Episodic Memory and Restores Cholinergic Dysfunction in Alzheimer's Disease	62
Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers	61
Regional Brain Growth Trajectories in Fetuses with Congenital Heart Disease	61
Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD	61
Comparative Effectiveness of Stereotactic Electroencephalography Versus Subdural Grids in Epilepsy Surgery	60
Meningeal CGRP‐Prolactin Interaction Evokes Female‐Specific Migraine Behavior	60
Targeting Inflammasomes to Treat Neurological Diseases	57
A Pilot Randomized, Controlled, Double‐Blind Trial of Bumetanide to Treat Neonatal Seizures	56
Characterizing the Genetic Architecture of Parkinson's Disease in Latinos	56
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis	54
Lewy Body–like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α‐Synuclein Mutations	52
Predictors of Long‐Term Outcome of Subthalamic Stimulation in Parkinson Disease	52
Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease	51
Superficial Siderosis: A Clinical Review	50
Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease	49